WEC
ACOR

Winslow Evans & Crocker’s Acorda Therapeutics ACOR Stock Holding History

Winslow Evans & Crocker’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-8
Closed -$1K – 1182
2020
Q2 		$1K Hold
8
– – ﹤0.01% 1119
2020
Q1 		$2K Buy
+8
New +$1.57K ﹤0.01% 1099

Other funds holding ACOR

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Winslow Evans & Crocker's ACOR Position: Q3 2020 in Review

Winslow Evans & Crocker sold out of Acorda Therapeutics (ACOR) in Q3 2020, closing a stake of 8 shares — an estimated $1K sold.

Winslow Evans & Crocker first reported a position in ACOR in Q1 2020 and held it in 2 quarters. The position peaked at $2K in Q1 2020. 60 funds tracked by Wall St. Rank hold ACOR as of Q3 2020.

  • Winslow Evans & Crocker reported no remaining Acorda Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Winslow Evans & Crocker sold 8 Acorda Therapeutics shares in Q3 2020, an estimated $1K.
  • Winslow Evans & Crocker first reported a position in Acorda Therapeutics in Q1 2020 and held it in 2 quarters.
  • Winslow Evans & Crocker's Acorda Therapeutics position peaked at $2K in Q1 2020.
  • 60 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2020.

Based on Winslow Evans & Crocker's 13F filing for Q3 2020, filed 21 Oct 2020.